Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study

Ravaud A, Cerny T, Terret C, Wanders J, Bui B, Hess D, Droz J, Fumoleau P, Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. European journal of cancer (Oxford, England : 1990) 2005; 41:702-7.